Biolase sees FY23 revenue $48.9M-$49.2M, consensus $49.21M

The company said, “The Company believes it is well positioned with its industry-leading dental lasers and broad intellectual property (“IP”) portfolio to capitalize on the significant market opportunity for dental laser adoption and, with the year-end cash and cash equivalents balance of $6.6 million, execute its growth strategies throughout 2024.”